Special Report: First Year After Launch 2013
Click to download the PDF to view the full issue Special Report First Year After Launch charts (Excel Document) For the global pharma arena, 2012 is noted as the year […]
About Andrew Humphreys
This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
Entries by Andrew Humphreys
23rd Annual Report 2013
Click to download the PDF to view the full issue Top 100 Med Sales Layout (Excel Document) Top 100 Medicine Highlights Humira claimed the worldwide sales crown from long-time champion […]
22nd Annual Report 2013
Top 100 Biotechnology Companies
Biotech industry growth is bolstered by increased R&D spending, an upswing of approved first-in-class medicines, elevated Wall Street valuations, and continued forging of pipeline alliances with Big Pharma.
Class warfare 2013
Click to download the PDF to view the full issue Pharmaceutical and biotechnology companies are fighting for diabetes market share via a variety of established and new innovative medicines. U.S. […]
Future blockbusters 2013
Click to download the PDF to view the full issue An upswing in NME approvals is an encouraging sign for an industry trying to overcome mega-brand patent expirations and a […]
93 New Medicines 2013
Click to download the PDF to view the full issue New Medicines List (Excel Document) FDA regulators during 2012 approved 39 new molecular entities, the highest amount in one year […]
Women’s Health Medicine Review 2013
Click to download the PDF to view the full issue As new blockbuster drugs emerge in the breast cancer setting, the industry is awaiting the next breakthrough products to reach […]
